These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 23762093)

  • 41. Clinical effects of bisphosphonates in involutional osteoporosis.
    Ott SM
    J Bone Miner Res; 1993 Dec; 8 Suppl 2():S597-606. PubMed ID: 8122531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin.
    French DL; Muir JM; Webber CE
    Phytomedicine; 2008 Dec; 15(12):1069-78. PubMed ID: 18693096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluorosis increases the risk of postmenopausal osteoporosis by stimulating interferon γ.
    Lv YG; Kang L; Wu G
    Biochem Biophys Res Commun; 2016 Oct; 479(2):372-379. PubMed ID: 27644876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spanish Menopause Society position statement: Use of denosumab in postmenopausal women.
    Cano A; Silvan JM; Estévez A; Baró F; Villero J; Quereda F; Ferrer J; Mendoza N; Sánchez-Borrego R;
    Maturitas; 2014 Sep; 79(1):117-21. PubMed ID: 25042873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
    Schultz TC; Valenzano JP; Verzella JL; Umland EM
    Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention.
    Karmakar S; Kay J; Gravallese EM
    Rheum Dis Clin North Am; 2010 May; 36(2):385-404. PubMed ID: 20510240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
    Allen MR; Erickson AM; Wang X; Burr DB; Martin RB; Hazelwood SJ
    Calcif Tissue Int; 2010 Jan; 86(1):67-71. PubMed ID: 19953232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical significance of wrist fracture in osteoporosis.
    Cerocchi I; Ghera S; Gasbarra E; Feola M; Tarantino U
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S81-2. PubMed ID: 24046048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].
    Endo I; Matsumoto T
    Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Menopause and bone].
    Lobersztajn A; Trémollières F
    J Gynecol Obstet Biol Reprod (Paris); 2012 Nov; 41(7 Suppl):F28-32. PubMed ID: 23036315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
    Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flufenamic acid inhibits osteoclast formation and bone resorption and act against estrogen-dependent bone loss in mice.
    Zhang S; Huo S; Li H; Tang H; Nie B; Qu X; Yue B
    Int Immunopharmacol; 2020 Jan; 78():106014. PubMed ID: 31776093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Osteoporosis and hormone replacement therapy].
    Roux C
    Presse Med; 2005 Mar; 34(5):379-84. PubMed ID: 15859575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Denosumab for treatment of postmenopausal osteoporosis.
    Chitre M; Shechter D; Grauer A
    Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.